The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia.
Arsenic trioxide (As2O3) has been shown to be even more effective than all-trans retinoid (ATRA) in the treatment of acute promyelocytic leukemia (APL). The combination of induction of apoptosis, induction of differentiation and inhibiting the proliferation, and killing of APL cells could be the main cellular mechanisms of As2O3 in APL treatment. As2O3 may affect APL cells by disturbing the activities of some important intracorporal enzymes, regulating the related gene expression and arresting the progression of cell cycle.
Zhang
P
P
Department of Internal Medicine, The First Medical College of Harbin Medical University, Heilongjiang Province, China.
D000328:Adult; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017209:Apoptosis; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002648:Child; D004305:Dose-Response Relationship, Drug; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects; D018922:HL-60 Cells / Q000187:drug effects; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000473:pathology; D010087:Oxides / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction; D014018:Tissue Distribution / Q000187:drug effects; D016896:Treatment Outcome; D014212:Tretinoin / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D014212:Tretinoin; D000077237:Arsenic Trioxide